deeptech Value proposition
Généthon, centre de R&D préclinique et clinique de médicaments de thérapie génique.
Created in 1990 and funded by AFM-TELETHON, Genethon, a pioneer in deciphering the human genome and identifying the genes associated with genetic diseases is today fully dedicated to the design and development of gene therapy treatments for rare diseases.
At Genethon more than 180 scientists, clinicians and engineers specialized in gene therapy drug development, from research to the clinic, have joined forces in order to provide these innovative treatments to patients affected with rare disorders. These treatments also pave the way for new therapeutic approaches for frequent disorders.
In 2012 Genethon received the Prix Galien France for pharmaceutical research into “Medicines destined for rare diseases – cell therapy and gene therapy.”
In 2013 Genethon’s production facility, Genethon BioProd obtained certification as a pharmaceutical manufacturer from French National agency for medicines and health products safety (ANSM). Genethon BioProd is the largest laboratory for GMP production of gene therapy products in the world.
In april 2015 Genethon was recipient of the Global Innovation Competition 2030 in the category “Risk Lift” at the Elysee Palace, for its project on the development of an industrial process for production of gene therapy vectors.
gene therapy, rare genetic disease, and clinical trialsOriginal language
Généthon, centre de R&D préclinique et clinique de médicaments de thérapie génique.
Created in 1990 and funded by AFM-TELETHON, Genethon, a pioneer in deciphering the human genome and identifying the genes associated with genetic diseases is today fully dedicated to the design and development of gene therapy treatments for rare diseases.
At Genethon more than 180 scientists, clinicians and engineers specialized in gene therapy drug development, from research to the clinic, have joined forces in order to provide these innovative treatments to patients affected with rare disorders. These treatments also pave the way for new therapeutic approaches for frequent disorders.
In 2012 Genethon received the Prix Galien France for pharmaceutical research into “Medicines destined for rare diseases – cell therapy and gene therapy.”
In 2013 Genethon’s production facility, Genethon BioProd obtained certification as a pharmaceutical manufacturer from French National agency for medicines and health products safety (ANSM). Genethon BioProd is the largest laboratory for GMP production of gene therapy products in the world.
In april 2015 Genethon was recipient of the Global Innovation Competition 2030 in the category “Risk Lift” at the Elysee Palace, for its project on the development of an industrial process for production of gene therapy vectors.
Généthon - Des médicaments de thérapie génique pour maladies rares
Généthon développe des thérapies géniques innovantes pour les maladies rares neuromusculaires, du système immunitaire, du sang, du foie et de la vision
https://www.genethon.fr/
| Corporate | Type | Tweets | Articles | |
|---|---|---|---|---|
 France Biotech Startup accelerator & VC, Biotechnology, Biotechnology Research | France Biotech Startup accelerator & VC, Biotechnology, Biotechnology Research | Other 19 Apr 2024 | | |
 Thales Defence and Aerospace, IT Services and IT Consulting | Thales Defence and Aerospace, IT Services and IT Consulting | Other 29 Jul 2023 | | |
 Bpifrance Bank, Banking | Bpifrance Bank, Banking | Other 18 Feb 2024 | | |
 Leem Startup accelerator & VC, Pharmaceutical Manufacturing | Leem Startup accelerator & VC, Pharmaceutical Manufacturing | Other 18 Feb 2024 | | |
 Greater Paris University Hospitals - AP-HP Health, Hospitals and Health Care | Greater Paris University Hospitals - AP-HP Health, Hospitals and Health Care | Other 17 Aug 2023 | | |
 Genopole Biotechnology, Biotechnology Research | Genopole Biotechnology, Biotechnology Research | Not capitalistic Partnership Event 17 Aug 2023 | | |